The software, materials and assistance provided by iubenda have the only purpose of helping users with compliance regarding their legal requirements. In particular, the templates iubenda provides are generated automatically, yet every word of our template has been written and continuously revised by a skilled legal team. However, as can be easily understood, nothing can substitute a professional legal consultancy in the drafting of your privacy policy, cookie policy or of any other legal document or compliance procedure.
Our service does its best to provide you with a starting point, like an extremely sophisticated templates book, but even if we strive to provide the best assistance possible, we cannot guarantee any conformity with the law, which only a lawyer can do. Nothing on this site, therefore, shall be considered legal advice and no attorney-client relationship is established. Please note that in some cases, depending on your legislation, further actions may be required to make your activity compliant with the law.
Dr. Victor Tetz serves as a Scientific Advisor who is responsible for the strategic planning for TGV-Therapeutics. Prior to founding TGV-Therapeutics, Victor successfully worked in senior positions in drug development companies.
Dr. George Tetz serves as CEO. He comes from a rich background, including industrial, academic, and nonprofit organizations. Throughout his career, George Tetz has focused on applying leading-edge genomic approaches to a variety of medical problems.
Dr. Jeffrey A. Gelfand, serves as a Chairman of the Scientific Advisory Board. Dr. Jeffrey A. Gelfand is a Professor and Chairman of the Department of Medicine at Tufts and Physician-in-Chief at the New England Medical center. He is currently an attending physician at Massachusetts General Hospital, a Clinical Professor at Harvard Medical School, and Professor of Medicine at Tufts. Dr. Gelfand conducts laboratory and clinical research in immunology, inflammation, infection, and tumor immunology.
Dr. Michelle Welborn, serves as a pharmaceutical consultant and provides regulatory consulting to manage the project in FDA. Michelle Welborn holds a Doctor of Pharmacy degree from Campbell University School of Pharmacy.
Michelle has 15 years experience in pharmaceuticals as a liaison in Medical and Regulatory Affairs for both Astra-Merck and Sanofi –Aventis Pharmaceuticals, and as Clinical Pharmacy Manager for a Health Maintenance Organization (HMO) , and as a Pharmacy Practice resident at Wake Forest University Baptist Medical CenterShe has participated in workshops and consortiums organized by the NIH (National Institutes of Health), the National Organization of Rare Diseases (NORD), the International Congress of Rare Diseases (ICORD), and the Centers for Disease Control (CDC), the Epilepsy Foundation of America, and the Australian Dravet syndrome Family Day.
She served for two years as the Professional Advisory Board Chair for the IDEA League before founding ICE. She currently serves on the Professional Advisory Boards for the Charlie Foundation and Lennox-Gastaut Syndrome Foundation.
Dr Sushant is responsible for the management of all operational aspects and investment.
Dr, Cynamon serves as a Member of Scientific Advisory Board. Dr. Michael Cynamon is an infectious disease specialist in Syracuse, New York and is affiliated with Syracuse Veterans Affairs Medical Center. He received his medical degree from Yale University School of Medicine and has been in practice for 43 years.He is a leading researcher in pulmonary infections with more than 35 years experience in healthcare research.